메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Ja Young Han (Fairleigh Dickinson University) So Young Lee (Sookmyung Women's University) Eun Cho (Sookmyung Women's University)
저널정보
한국보건의료기술평가학회 보건의료기술평가 보건의료기술평가 제11권 제1호
발행연도
2023.6
수록면
58 - 63 (6page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Objectives: Synovial sarcoma (SS) is a histological subtype of soft tissue sarcoma (STS) with a high rate of metastasis and/or recurrence. Pazopanib is the only targeted therapy approved by FDA to treat advanced STS. To estimate the real-world effectiveness of pazopanib on advanced SS through a systematic literature review and meta-analysis. Methods: Medline was searched from January 1, 2012 to December 31, 2020, with the keywords of pazopanib AND soft AND tissue AND sarcoma. The Preferred Reporting Item for Systematic Reviews and Meta-analysis (PRISMA) guidelines were used. Observational studies in adults with advanced SS were included. Studies that did not report the histology-specific outcomes were excluded. Effectiveness outcomes included response rate (RR) (complete response [CR] and partial response [PR]) and clinical benefit (CR and PR plus stable disease [SD]). Considering the additional uncertainty associated with the effects of treatment, a random- effects model was performed using R version 4.1.1. Heterogeneity was assessed using the inconsistency index (I2). Sensitivity analysis was conducted with a broader definition of SD. Results: Of 263 potentially relevant studies identified, seven observational studies were included in the meta- analysis. A total of 94 adult patients with advanced SS were included and the median sample size was 14. Three studies were conducted in South Korea and the remaining four studies were conducted in various countries. Five studies reported median progression-free survival in addition to tumor responses. The estimated RR of pazopanib was 16.4% (95% confidence interval [CI]: 0.05 to 0.28; I2=60%) and 62.9% of patients showed clinical benefit (95% CI: 0.44 to 0.82; I2=74%). Conclusion: Pazopanib controlled advanced SS as effectively as first-line chemotherapy. With increasing emphasis being given to understanding the histology-specific treatment effect, the present study adds important information to the existing literature on the treatment of advanced SS.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

최근 본 자료

전체보기

댓글(0)

0